Lesaffre, an independent French key global player in fermentation and microorganisms, and CanBiocin, Canadian global leader in species-specific companion animal and livestock probiotic development, announce a major strategic investment by Lesaffre into CanBiocin to offer an extended cutting-edge portfolio of pet care solutions to a global customer base.
Thanks to the combination of complementary strengths and strong synergy between proprietary portfolios, CanBiocin and Phileo, a Lesaffre business unit will join forces to offer extended and robust innovative portfolio of probiotic solutions tailored to the unique needs of companion animals.
Synergies will emerge while leveraging both companies’ strengths: Lesaffre’s global presence, extensive industrial network, Phileo’s innovation acceleration capabilities, and CanBiocin’s complementary expertise in bacterial screening, strain isolation from ancestral and primordial sources, and advanced microencapsulation formulation techniques. Therefore, this collaboration will provide unique combinations of natural and sustainable ingredients for animal health and wellness.
For Phileo by Lesaffre, this major strategic investment in CanBiocin strengthens its ability to deliver comprehensive solutions across companion animal care, food and supplements. Coupled with Lesaffre’s recent acquisition of a majority stake in Biorigin—Brazilian specialists in natural-origin ingredients —Phileo significantly expands its companion animal care market presence. By harnessing the complementary portfolios of CanBiocin and Biorigin, alongside Lesaffre’s global reach, Phileo is strategically positioned to address the total companion animal care ecosystem with innovative, cutting-edge solutions that enhance companion animal health and well-being worldwide.
“This strategic move perfectly aligns with Lesaffre’s unwavering commitment to customer proximity. Together with CanBiocin with whom we share common values, we will expand our ability to provide comprehensive offerings and extensive portfolios that address our clients’ complete needs with end-to-end solutions,” said Brice-Audren Riché, CEO of Lesaffre. “We are confident that the combination of Phileo’s and CanBiocin’s expertise will allow us to better serve the evolving needs of pet owners and animal feed producers worldwide.”
“This investment marks an important step for Phileo by Lesaffre to expand our footprint in both companion animal food and supplements with a special focus on pets. With this strategic investment Phileo by Lesaffre expands its presence in Pet Care Market,” said Manuel Maire, General Manager Phileo by Lesaffre.”CanBiocin’s expertise in novel probiotic strains perfectly complements our leadership in yeast probiotics and postbiotics, building on the success of our flagship yeast probiotic, Actisaf®. This reinforces our commitment to the companion animal care market and our focus on innovative microbial solutions for companion animal health and wellness.”
“Joining forces with Phileo will allow us to accelerate the development and commercialization of our innovative products for the pet care and livestock sectors globally,” said, Dr. J.F. (Jake) Burlet CEO of CanBiocin. “We were first introduced to Lesaffre’s Phileo business unit about 4 ½ years ago. We have maintained contact with key personnel at Phileo over the years. Common values, strategic long-term thinking and market positioning allowed us to begin a conversation about something bigger – ultimately resulted in this transformative investment to grow both CanBiocin and Phileo businesses”.